海尔生物
(688139)
| 流通市值：104.16亿 | | | 总市值：104.16亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,195,500,051.78 | 688,989,400.7 | 2,283,832,911.43 | 1,782,020,224.83 |
| 营业收入 | 1,195,500,051.78 | 688,989,400.7 | 2,283,832,911.43 | 1,782,020,224.83 |
| 二、营业总成本 | 1,066,058,361.3 | 575,353,290.72 | 1,941,857,521.47 | 1,468,536,204.53 |
| 营业成本 | 642,201,576.13 | 355,833,943.97 | 1,187,914,554.76 | 917,519,524.02 |
| 税金及附加 | 11,302,560.43 | 7,029,318.27 | 23,293,190.71 | 15,744,301.58 |
| 销售费用 | 173,897,821.56 | 90,073,206.11 | 290,373,566.16 | 211,737,388.26 |
| 管理费用 | 95,964,069.93 | 47,989,485.05 | 181,359,437.04 | 133,850,540.5 |
| 研发费用 | 160,107,590.16 | 80,452,189.16 | 306,171,076.92 | 223,579,922.81 |
| 财务费用 | -17,415,256.91 | -6,024,851.84 | -47,254,304.12 | -33,895,472.64 |
| 其中:利息费用 | 1,916,197.01 | 976,876.36 | 3,410,319.59 | 2,470,544.38 |
| 其中:利息收入 | 16,054,023.05 | 8,771,449.17 | 47,662,107.06 | 37,578,315.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,894,977.61 | 219,653.28 | 5,468,787.54 | -172,721 |
| 加:投资收益 | 15,907,644.87 | 7,530,986.84 | 23,794,761.37 | 16,606,073.73 |
| 资产处置收益 | -18,792.77 | -38,090.35 | 233,571.76 | -124,596.66 |
| 资产减值损失(新) | -2,932,521.61 | -820,178.91 | -2,756,186.74 | -1,755,038.72 |
| 信用减值损失(新) | -11,508,828.9 | -7,133,412.84 | -15,535,293.57 | -19,364,586.03 |
| 其他收益 | 24,753,524.61 | 13,151,143.91 | 48,646,778.42 | 32,131,652.64 |
| 四、营业利润 | 157,537,694.29 | 126,546,211.91 | 401,827,808.74 | 340,804,804.26 |
| 加:营业外收入 | 390,737.12 | 121,649.36 | 3,247,061.03 | 2,970,937.9 |
| 减:营业外支出 | 1,735,387.71 | 1,177,982.82 | 3,118,165.04 | 1,357,245.63 |
| 五、利润总额 | 156,193,043.7 | 125,489,878.45 | 401,956,704.73 | 342,418,496.53 |
| 减:所得税费用 | 8,980,002.3 | 9,291,909.26 | 20,948,658.93 | 23,440,550.64 |
| 六、净利润 | 147,213,041.4 | 116,197,969.19 | 381,008,045.8 | 318,977,945.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 147,213,041.4 | 116,197,969.19 | 381,008,045.8 | 318,977,945.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 142,739,180.8 | 110,258,240.35 | 366,632,797.05 | 309,141,846.32 |
| 少数股东损益 | 4,473,860.6 | 5,939,728.84 | 14,375,248.75 | 9,836,099.57 |
| 扣除非经常损益后的净利润 | 123,484,524.2 | 99,168,300.25 | 321,803,539.26 | 276,229,678.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.35 | 1.16 | 0.98 |
| (二)稀释每股收益 | 0.45 | 0.35 | 1.16 | 0.98 |
| 八、其他综合收益 | 625,201.66 | 457,278.77 | -13,065,819.88 | -23,664,262.3 |
| 归属于母公司股东的其他综合收益 | 625,201.66 | 457,278.77 | -13,065,819.88 | -23,664,262.3 |
| 九、综合收益总额 | 147,838,243.06 | 116,655,247.96 | 367,942,225.92 | 295,313,683.59 |
| 归属于母公司股东的综合收益总额 | 143,364,382.46 | 110,715,519.12 | 353,566,977.17 | 285,477,584.02 |
| 归属于少数股东的综合收益总额 | 4,473,860.6 | 5,939,728.84 | 14,375,248.75 | 9,836,099.57 |
| 公告日期 | 2025-08-27 | 2025-04-30 | 2025-03-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |